Viatris (VTRS) Debt/Equity Ratio: History & Chart

Viatris Inc. (VTRS)VTRSViatris Inc.

About Viatris Inc.

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Canonsburg, PA

30,000 employees

www.viatris.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Scott Andrew Smith

View full financials

VTRS Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.94

DEBT TO EQUITY RATIO AVG TTM

0.97

DEBT TO EQUITY RATIO AVG 3Y

0.93

DEBT TO EQUITY RATIO AVG 5Y

0.97

DEBT TO EQUITY RATIO AVG 10Y

1.06

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-3.06%

CURRENT VS 3Y AVG

+0.50%

CURRENT VS 5Y AVG

-3.20%

CURRENT VS 10Y AVG

-11.60%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.66

median of 76 covered companies

CURRENT VS SECTOR MEDIAN

+41.86%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Viatris Inc. (VTRS)	$19.31B	0.94	0.97	0.93	0.97
Zimmer Biomet Holdings, Inc. (ZBH)vs ›	$18.60B	0.59	0.54	0.51	0.54
Hologic, Inc. (HOLX)vs ›	$16.97B	0.48	0.52	0.55	0.69
Medpace Holdings, Inc. (MEDP)vs ›	$16.31B	0.28	0.36	0.37	0.29
United Therapeutics Corporation (UTHR)vs ›	$22.54B	N/A	0.03	0.09	0.13
Moderna, Inc. (MRNA)vs ›	$22.85B	0.18	0.15	0.11	0.10
STERIS plc (STE)vs ›	$23.08B	0.03	0.31	0.42	0.44
BioNTech SE (BNTX)vs ›	$23.24B	0.02	0.01	0.01	0.04
The Cooper Companies, Inc. (COO)vs ›	$14.46B	0.30	0.33	0.35	0.36
Solventum Corporation (SOLV)vs ›	$14.31B	1.06	1.85	1.11	0.89

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Viatris Inc. (VTRS)

$19.31B

0.94

0.97

0.93

0.97

Zimmer Biomet Holdings, Inc. (ZBH)vs ›

$18.60B

0.59

0.54

0.51

0.54

Hologic, Inc. (HOLX)vs ›

$16.97B

0.48

0.52

0.55

0.69

Medpace Holdings, Inc. (MEDP)vs ›

$16.31B

0.28

0.36

0.37

0.29

United Therapeutics Corporation (UTHR)vs ›

$22.54B

N/A

0.03

0.09

0.13

Moderna, Inc. (MRNA)vs ›

$22.85B

0.18

0.15

0.11

0.10

STERIS plc (STE)vs ›

$23.08B

0.03

0.31

0.42

0.44

BioNTech SE (BNTX)vs ›

$23.24B

0.02

0.01

0.04

The Cooper Companies, Inc. (COO)vs ›

$14.46B

0.30

0.33

0.35

0.36

Solventum Corporation (SOLV)vs ›

$14.31B

1.06

1.85

1.11

0.89

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Viatris Inc. (VTRS)?

The debt to equity ratio for VTRS stock is 0.94.

Is Viatris Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.94 is in line with its 5-year average of 0.97, around the middle of its 5-year range (0.77–1.16).

What is the TTM average debt to equity ratio for Viatris Inc. (VTRS)?

The TTM average debt to equity ratio for VTRS stock is 0.97.

What is the 3Y average debt to equity ratio for Viatris Inc. (VTRS)?

The 3Y average debt to equity ratio for VTRS stock is 0.93.

What is the 5Y average debt to equity ratio for Viatris Inc. (VTRS)?

The 5Y average debt to equity ratio for VTRS stock is 0.97.

What is the 10Y average debt to equity ratio for Viatris Inc. (VTRS)?

The 10Y average debt to equity ratio for VTRS stock is 1.06.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.94
2026-03-31	0.98
2025-12-31	1.00
2025-09-30	0.97
2025-06-30	0.95
2025-03-31	0.92
2024-12-31	0.77
2024-09-30	0.81
2024-06-30	0.89
2024-03-31	0.91
2023-12-31	0.90
2023-09-30	0.89
2023-06-30	0.90
2023-03-31	0.91
2022-12-31	0.93
2022-09-30	1.06
2022-06-30	1.07
2022-03-31	1.09
2021-12-31	1.14
2021-09-30	1.12
2021-06-30	1.16
2021-03-31	1.16
2020-12-31	1.14
2020-09-27	1.00
2020-06-28	1.06
2020-03-29	1.15
2019-12-31	1.09
2019-09-29	1.14
2019-06-29	1.12
2019-03-30	1.16
2018-12-30	1.14
2018-09-29	1.20
2018-06-29	1.20
2018-03-30	1.14
2017-12-30	1.10
2017-09-29	1.11
2017-06-29	1.17
2017-03-30	1.28
2016-12-30	1.39
2016-09-29	1.32
2016-06-29	1.29
2016-03-30	0.73
2015-12-30	0.75
2015-09-29	0.66
2015-06-29	0.89
2015-03-30	0.95
2014-12-30	2.61
2014-09-29	2.37
2014-06-29	2.47
2014-03-30	2.57
2013-12-30	2.73
2013-09-29	1.96

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.94

2026-03-31

0.98

2025-12-31

1.00

2025-09-30

0.97

2025-06-30

0.95

2025-03-31

0.92

2024-12-31

0.77

2024-09-30

0.81

2024-06-30

0.89

2024-03-31

0.91

2023-12-31

0.90

2023-09-30

0.89

2023-06-30

0.90

2023-03-31

0.91

2022-12-31

0.93

2022-09-30

1.06

2022-06-30

1.07

2022-03-31

1.09

2021-12-31

1.14

2021-09-30

1.12

2021-06-30

1.16

2021-03-31

1.16

2020-12-31

1.14

2020-09-27

1.00

2020-06-28

1.06

2020-03-29

1.15

2019-12-31

1.09

2019-09-29

1.14

2019-06-29

1.12

2019-03-30

1.16

2018-12-30

1.14

2018-09-29

1.20

2018-06-29

1.20

2018-03-30

1.14

2017-12-30

1.10

2017-09-29

1.11

2017-06-29

1.17

2017-03-30

1.28

2016-12-30

1.39

2016-09-29

1.32

2016-06-29

1.29

2016-03-30

0.73

2015-12-30

0.75

2015-09-29

0.66

2015-06-29

0.89

2015-03-30

0.95

2014-12-30

2.61

2014-09-29

2.37

2014-06-29

2.47

2014-03-30

2.57

2013-12-30

2.73

2013-09-29

1.96

Debt to Equity Ratio: 0.94

VTRS Debt to Equity Ratio

VTRS Average Debt to Equity Ratio Chart

VTRS Current vs Average Debt to Equity Ratio Chart

VTRS Debt to Equity Ratio Metrics

VTRS Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

VTRS Debt to Equity Ratio History

Related Metrics